quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:20:00·52d
PRRelease
Dyadic International Inc. logo

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

DYAI· Dyadic International Inc.
Health Care
Original source

Companies

  • DYAI
    Dyadic International Inc.
    Health Care

Recent analyst ratings

  • Oct 23UpdateH.C. Wainwright$3.00
  • Sep 8UpdateCraig Hallum-
  • Jul 18UpdateDawson James-
  • Dec 17UpdateHC Wainwright & Co.$7.00

Related

  • SEC27d
    SEC Form 8-K filed by Dyadic International Inc.
  • PR29d
    Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
  • SEC29d
    Dyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC29d
    SEC Form 10-K filed by Dyadic International Inc.
  • PR38d
    Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
  • PR41d
    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
  • PR43d
    Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
  • PR44d
    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022